U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07278505) titled 'Study of Cannabidiol and Neuroimaging on Stress' on Dec. 03.
Brief Summary: Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. To address this gap, the investigators propose a rigorous translational neuroscience study in a clinical high-risk population to define the roles of CBD in stress response with mechanisms of mesocorticolimbic-network functi...